Citations

Mayo Clinic

Clear

3307 citation(s) found for "Jäck, Alexander".

Thoracic Aortic Dissection in Tetralogy of Fallot: A Review of the National Inpatient Sample Database
Egbe, Alexander C. , Miranda, William R. , Connolly, Heidi M. , Crestanello, Juan A.

Journal of the American Heart Association | March 15, 2019 | Volume: 8 | Issue: 6 | Pages: No page available

10.1161/jaha.119.011943 | PMID 30871391 Get It

Background Thoracic aortic aneurysm is common in patients with tetralogy of Fallot ( TOF ); the incidence of thoracic aortic dissection ( TAD ) is unknown, but generally considered to be uncommon. The purpose of this study was to determine incidence and risk factors for TAD in TOF patients. Methods and Results This work is a retrospective review of the National Inpatient Sample ( NIS ) database for cases of ascending TAD among all hospital admissions in adults with TOF , 2000–2014. Of 18 353 admissions in TOF patients, 11 (0.06%; 6 per 10 000 admissions) of these were TAD ‐related admissions. For the TAD ‐related admissions, mean age was 49.8±7.2 years; aortic surgical interventions were performed during 8 of the admissions, and overall in‐hospital mortality was 45% (5 of 11). Risk factors associated with TAD ‐related admission were age >60 years (odds ratio, 2.41; 95% CI, 1.23–3.25; P =0.013), male sex ( odds ratio, 6.91; 95% CI, 4.85–8.54; P <0.001), and hypertension (odds ratio, 1.74; 95% CI, 1.06–3.19; P =0.037). Conclusions This is the first population‐based study of TAD outcomes in patients with TOF , and it showed a low risk of TAD in this population. This has important clinical implication with regard to surveillance and surgical intervention. Given that prevalence of thoracic aortic aneurysm is higher in TOF patients compared with the general population; therefore, making clinical decisions based on outcomes data and practice guidelines derived from patients with degenerative and bicuspid aortic valve–related aortopathies may lead to overtreatment . Further studies are required to better understand the pathobiology of this disease in order to make evidence‐based recommendations for surveillance and treatment.
Associations Between In-Hospital Mortality, Health Care Utilization, and Inpatient Costs With the 2011 Resident Duty Hour Revision
Eid, Shaker M. , Ponor, Lucia, Reed, Darcy A. , Beydoun, Hind A. , Beydoun, May A. , Wright, Scott M.

Journal of Graduate Medical Education | March 14, 2019 | Volume: 11 | Issue: 2 | Pages: 146-155

10.4300/jgme-d-18-00415.1 | PMID 31024645 Get It

ABSTRACT Background The Accreditation Council for Graduate Medical Education (ACGME) has mandated revisions to residents' work hours to improve patient safety and enhance resident education and wellness. The impact on clinical outcomes on a national level is poorly understood. Objective We examined data from before and after the ACGME 2011 duty hour revision and looked for differences between teaching and nonteaching US hospitals. Methods A retrospective observational study of patients admitted to hospitals in the 2-year periods before and after the 2011 duty hour revision was conducted, utilizing a nationally representative data set. We compared patient and hospital characteristics using standardized differences. With nonteaching hospitals serving as the control group, we used multiple group interrupted time series segmented regression analysis to test for postrevision level and trend changes in mortality, length of stay (LOS), and costs. Results We examined more than 117 million hospitalizations. At teaching and nonteaching hospitals, trends in mortality and LOS in prerevision and postrevision periods were not significantly different (all P &gt; .05). A significant monthly reduction in cost per hospitalization was noted postrevision at teaching hospitals (P = .019) but not at nonteaching hospitals (P = .62). In the 2 years following the 2011 revision, there was a monthly reduction in cost per hospitalization (–$52.28; 95% confidence interval –$116.90 to –$12.32; P = .026) at teaching relative to nonteaching hospitals. Conclusions There were no differences in mortality or LOS between teaching and nonteaching hospitals. However, there was a small decrease in cost per hospitalization at teaching hospitals following the 2011 revision.
Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases
Romagnoli, Micaela , Colby, Thomas V. , Berthet, Jean‐Philippe, Gamez, Anne Sophie, Mallet, Jean‐Pierre , Serre, Isabelle, Cancellieri, Alessandra , Solovei, Laurence , Dell’Amore, Andrea , Dolci, Giampiero , Guerrieri, Aldo, Reynaud, Paul, Bommart, Sébastien , Zompatori, Maurizio , Dalpiaz, Giorgia , Trisolini, Rocco , Suehs, Carey , Bourdin, Arnaud , Dell'Amore, Andrea , Dolci, Giampiero , Bommart, Sébastien , Trisolini, Rocco , Suehs, Carey M , Vachier, Isabelle , Molinari, Nicolas , Bourdin, Arnaud , Reynaud, Paul, Nava, Stefano , Vachier, Isabelle , Molinari, Nicolas

American Journal of Respiratory and Critical Care Medicine | March 13, 2019 | Volume: 199 | Issue: 10 | Pages: 1249-1256

10.1164/rccm.201810-1947oc | PMID 30864813 Get It

Abstract Rationale The diagnostic concordance between transbronchial lung cryobiopsy (TBLC)—versus surgical lung biopsy (SLB) as the current gold standard—in interstitial lung disease (ILD) cases requiring histology remains controversial. Objectives To assess diagnostic concordance between TBLC and SLB sequentially performed in the same patients, the diagnostic yield of both techniques, and subsequent changes in multidisciplinary assessment (MDA) decisions. Methods A two-center prospective study included patients with ILD with a nondefinite usual interstitial pneumonia pattern (on high-resolution computed tomography scan) confirmed at a first MDA. Patients underwent TBLC immediately followed by video-assisted thoracoscopy for SLB at the same anatomical locations. After open reading of both sample types by local pathologists and final diagnosis at a second MDA (MDA2), anonymized TBLC and SLB slides were blindly assessed by an external expert pathologist (T.V.C.). Kappa-concordance coefficients and percentage agreement were computed for: TBLC versus SLB, MDA2 versus TBLC, MDA2 versus SLB, and blinded pathology versus routine pathology. Measurements and Main Results Twenty-one patients were included. The median TBLC biopsy size (longest axis) was 7 mm (interquartile range, 5–8 mm). SLB biopsy sizes averaged 46.1 ± 13.8 mm. Concordance coefficients and percentage agreement were: TBLC versus SLB: κ = 0.22 (95% confidence interval [CI], 0.01–0.44), percentage agreement = 38% (95% CI, 18–62%); MDA2 versus TBLC: κ = 0.31 (95% CI, 0.06–0.56), percentage agreement = 48% (95% CI, 26–70)%; MDA2 versus SLB: κ = 0.51 (95% CI, 0.27–0.75), percentage agreement = 62% (95% CI, 38–82%); two pneumothoraces (9.5%) were recorded during TBLC. TBLC would have led to a different treatment if SLB was not performed in 11 of 21 (52%) of cases. Conclusions Pathological results from TBLC and SLB were poorly concordant in the assessment of ILD. SLBs were more frequently concordant with the final diagnosis retained at MDA.
Current Practice Trends in Image Guidance During Lumbar and Cervical Transforaminal Epidural Steroid Injections
Vydra, Darrell , Hynes, Alexander, Clements, Nate, Julia, Jonathon, Schneider, Byron J. , Maus, Timothy P. , Cushman, Daniel M. , McCormick, Zachary L. , Nagpal, Ameet

Pain Medicine | March 12, 2019 | Volume: 20 | Issue: 11 | Pages: 2327-2329

10.1093/pm/pnz065 | PMID 30938803 Get It

Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Ellis, Paul Anthony, Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Burris, Howard A. , Strasak, Alexander, Patre, Monika, Perez, Edith A. , Toi, Masakazu , Conte, PierFranco , Martín, Miguel , Pieńkowski, Tadeusz , Pivot, Xavier B.

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 507-507

10.1200/jco.2015.33.15_suppl.507 Get It

Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.
Paterson, Alexander , Lew, Danika L., Hayes, Daniel F. , Schubert, Mark, Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Livingston, Robert B., Gralow, Julie R. , Barlow, William E. , Stopeck, Alison , Hershman, Dawn L. , Clemons, Mark , Ingle, James N. , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 503-503

10.1200/jco.2015.33.15_suppl.503 Get It

Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.
Chanan‐Khan, Asher , Fraser, Graeme , Silva, Rodrigo Santucci, Pylypenko, Halyna, Janssens, Ann , Pristupa, Alexander , Mayer, Jiří , Dilhuydy, Marie‐Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon , Sun, Steven , Mahler, Michelle, Salman, Mariya, Howes, Angela, Cramer, Paula , Demırkan, Fatih , Grosicki, Sebastian , Bartlett, Nancy L. , Hallek, Michael

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: LBA7005-LBA7005

10.1200/jco.2015.33.15_suppl.lba7005 Get It

Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors.
Wilcoxen, Keith, Becker, Marc A., Neff, Christopher, Abkevich, Victor, Jones, Joshua T., Hou, Xiaonan , Wang, Yan , Hartman, Anne‐Renee , AlHilli, Mariam , Gutin, Alexander , Agarwal, Shefali , Timms, Kirsten M. , Neff, Chris, Haluska, Paul

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5532-5532

10.1200/jco.2015.33.15_suppl.5532 Get It

A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of
Lheureux, Stéphanie , Weberpals, Johanne I. , Hendrickson, Andrea E. Wahner , Olawaiye, Alexander , Mackay, Helen , Wilson, Michelle , Rodríguez-Freixinós, Víctor, Martín-Lorente, Cristina, Ward, Jacklyn, Chang, Karen, Wang, Lisa , Speers, Vanessa , Karakasis, Katherine, Bowering, Valerie , Chen, Alice P. , Fleming, Gini F. , Braña, Irene , Dhani, Neesha C. , Chang, Karen, Brenton, James D. , Oza, Amit M.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS5613-TPS5613

10.1200/jco.2015.33.15_suppl.tps5613 Get It